COMMUNIQUÉS West-GlobeNewswire

Gate Bioscience Expands Collaboration and License Agreement with Lilly to Target Difficult-to-Drug Proteins
05/10/2026
Multi-year expansion of the companies’ 2025 agreement to use Gate’s Molecular Gate drug discovery engine to design molecular gate medicines for Lilly targets BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Gate [...]
Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101
05/10/2026
Constructive FDA interaction provides clear framework for RAD101 pivotal clinical development plan in brain metastases imaging Currently executing Phase 3 readiness activities in anticipation of FDA meeting minutes in [...]
Cannara Expands International Supply Agreement with Curaleaf
05/10/2026
MONTREAL, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, the “ Company ”, “ us ” or “ we ”) ( TSX: LOVE ) ( OTCQX: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
PDAOAI Opens BIO REBOOT Collaboration and Showcases Partitioned Literature Aggregation at Drug Discovery 2026
05/10/2026
Oncotelic’s AI drug discovery platform invites scientists, developers and biotech founders to connect computational discovery with drug development. Source: Oncotelic Therapeutics, Inc. AGOURA HILLS, Calif., Oct. 05, [...]
Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing
05/10/2026
ORION CORPORATION PRESS RELEASE 05 OCTOBER 2026 at 8:00am ET Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing Milestone [...]
Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
05/10/2026
Rapid oral presentation of additional sub-group analyses from the VIKTORIA-1 PIK3CA mutant-type cohort Poster presentation of a comparative analysis of data for the gedatolisib triplet from the PIK3CA wild-type cohort [...]
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
05/10/2026
Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, compared to the daily [...]
Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom
05/10/2026
– Expands patient access to opioid-sparing pain control and advances 5x30 strategy – BRISBANE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to [...]
Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)
05/10/2026
~ Acceptance into ETP enables early FDA engagement to support development of the RaniPill® platform technology ~ SAN JOSE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a [...]
vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)
05/10/2026
Milestone advances Phase 3 program toward topline results expected in mid 2027 HIGH POINT, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing [...]
Sofwave to Participate in the Jefferies Private MedTech Virtual Summit
05/10/2026
SAN CLEMENTE, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today [...]
Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026
05/10/2026
Presentations include real-world XPHOZAH® (tenapanor) data and new insights into hyperphosphatemia management and outcomes WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial- [...]
ApolloMD Expands Support of Emergency Medicine Foundation with New Research Grant and Annual Contribution
05/10/2026
ATLANTA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- ApolloMD is strengthening its partnership with the Emergency Medicine Foundation (EMF) through a new $15,000 research grant focused on emergency physician well-being and a $5, [...]
DLH Wins $2 Million NIH Data Governance Pilot Task Order
05/10/2026
ATLANTA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of digital, engineering, and scientific solutions for health and defense missions, today [...]
Aprea Therapeutics to Present at October Conferences
05/10/2026
Company to participate in 2026 Maxim Growth Summit (October 14) and Regional Biotechnology Conference (October 15) DOYLESTOWN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or [...]
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
05/10/2026
BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, [...]
Novo Nordisk A/S – Share repurchase programme
05/10/2026
Bagsværd, Denmark, 5 October 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR [...]
Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
05/10/2026
LOS ANGELES, CA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in AL Amyloidosis, today announced that it will present at the 45th Annual J.P. [...]
Freya Biosciences named as one of Fierce Biotech’s “Fierce 15” for 2026
05/10/2026
Recognition reflects Freya’s scientific progress and commitment to addressing significant unmet needs in women’s health COPENHAGEN, Denmark and BOSTON, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Freya Biosciences (“Freya” or “ [...]

Pages